WT1 and cancer: For example, the WT1-specific TCR used in our study was prepared by screening tens of healthy donors [7] and engineered to reduce cross-pairing with endogenous TCRs—such an approach is not possible for patients with rapidly progressing cancers with limited therapeutic intervention time.